Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joohyuk Sohn

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
Therapeutic Advances in Medical Oncology|January 30, 2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)Sun Kyung Baek, Jae-Ho Jeong, KyungHae Jung, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
The New England Journal of Medicine|December 11, 2024
Imlunestrant with or without Abemaciclib in Advanced Breast CancerKomal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, et al.
BMC Cancer|August 10, 2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, et al.
The New England Journal of Medicine|June 6, 2022
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, William Jacot, Toshinari Yamashita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
Therapeutic Advances in Medical Oncology|January 30, 2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)Sun Kyung Baek, Jae-Ho Jeong, KyungHae Jung, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
The New England Journal of Medicine|December 11, 2024
Imlunestrant with or without Abemaciclib in Advanced Breast CancerKomal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, et al.
BMC Cancer|August 10, 2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, et al.
The New England Journal of Medicine|June 6, 2022
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, William Jacot, Toshinari Yamashita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Pageof 13